Is AstraZeneca plc’s Latest Director Deal A Game-Changer?

With AstraZeneca plc (LON:AZN)’s CEO buying shares this week, is it a significant event for investors?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZenecaHaving been the subject of numerous bid approaches in recent months from US peer Pfizer, AstraZeneca (LSE: AZN) (NYSE: AZN.US) has now seen CEO Pascal Soriot buy around £2 million of shares in the company. The price he paid was £43.45 per share, which is within 10% of their five-year high. Does this mean that even after share price gains of 38% over the last year he is still extremely bullish on the company’s prospects? Or should investors in AstraZeneca lock in recent gains?

A New Pipeline

Clearly, AstraZeneca remains something of a turnaround story. Although over the medium to long term its pipeline is now in a much better state than it was even a year or two ago after the company has made a number of key acquisitions, AstraZeneca’s short-term outlook remains rather disappointing. For example, earnings per share (EPS) are expected to fall by 15% this year and by 3% next year, which indicates that the CEO is looking beyond the next couple of years and focusing on the longer term potential of the pipeline.

Short Term vs Long Term

Indeed, the fact that AstraZeneca’s CEO has bought shares in the company indicates that there are no fresh takeover talks taking place. Therefore, with earnings set to decline over the next couple of years, it could be the case that AstraZeneca’s current valuation comes under pressure. That’s because it was boosted by the Pfizer bids and it would not be a major surprise for it to drift back towards pre-bid levels. Of course, that’s not to say that AstraZeneca doesn’t have growth potential over the long run (it certainly does), but it does mean that the pace of recent gains may not be repeated until the company starts to deliver on its potential.

Sector Peers

Clearly, AstraZeneca has significant long term potential and continues to boost its pipeline, which bodes well for investors. However, sector peers GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and Smith & Nephew (LSE: SN) could also prove to be winning plays in the long run. For example, GlaxoSmithKline currently offers a better yield than AstraZeneca (5.2% versus 3.8% for AstraZeneca), as well as a lower price to earnings (P/E) ratio of 15.2 (versus 17.4 for AstraZeneca). GlaxoSmithKline also has a strong pipeline and has cash to burn after the sale of its Lucozade and Ribena brands.

Similarly, Smith & Nephew could also prove to be a strong long-term performer. Its business model is more stable than that of AstraZeneca, with the company focusing on wound care and orthopaedic reconstruction as opposed to the development of new drugs. Smith & Nephew trades on a relatively high P/E of 20.8, but offers double-digit EPS growth over the next two years. This means that shares in the company could continue to rise after gaining 40% in the last year alone.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter owns shares in GlaxoSmithKline and AstraZeneca. The Motley Fool has recommended shares in GlaxoSmithKline and owns shares in Smith & Nephew.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »